- Home
- ERAS vs GLAD Comparison
ERAS vs GLAD Comparison
Compare ERAS & GLAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- GLAD
- Stock Information
- Founded
- ERAS 2018
- GLAD 2001
- Country
- ERAS United States
- GLAD United States
- Employees
- ERAS N/A
- GLAD N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- GLAD Finance/Investors Services
- Sector
- ERAS Health Care
- GLAD Finance
- Exchange
- ERAS Nasdaq
- GLAD Nasdaq
- Market Cap
- ERAS 439.7M
- GLAD 482.1M
- IPO Year
- ERAS 2021
- GLAD N/A
- Fundamental
- Price
- ERAS $2.86
- GLAD $19.88
- Analyst Decision
- ERAS Buy
- GLAD Hold
- Analyst Count
- ERAS 6
- GLAD 2
- Target Price
- ERAS $3.50
- GLAD $25.75
- AVG Volume (30 Days)
- ERAS 1.3M
- GLAD 216.2K
- Earning Date
- ERAS 11-12-2025
- GLAD 11-17-2025
- Dividend Yield
- ERAS N/A
- GLAD 10.47%
- EPS Growth
- ERAS N/A
- GLAD N/A
- EPS
- ERAS N/A
- GLAD 2.55
- Revenue
- ERAS N/A
- GLAD $89,122,000.00
- Revenue This Year
- ERAS N/A
- GLAD N/A
- Revenue Next Year
- ERAS N/A
- GLAD $16.05
- P/E Ratio
- ERAS N/A
- GLAD $7.79
- Revenue Growth
- ERAS N/A
- GLAD N/A
- 52 Week Low
- ERAS $1.01
- GLAD $18.76
- 52 Week High
- ERAS $3.30
- GLAD $30.43
- Technical
- Relative Strength Index (RSI)
- ERAS 69.19
- GLAD 50.92
- Support Level
- ERAS $2.21
- GLAD $18.76
- Resistance Level
- ERAS $2.90
- GLAD $19.65
- Average True Range (ATR)
- ERAS 0.20
- GLAD 0.39
- MACD
- ERAS 0.04
- GLAD 0.15
- Stochastic Oscillator
- ERAS 96.19
- GLAD 97.48
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.